leisure time -WSS

leisure time

author：focus 2025-10-02 10:45:28 - browse：74

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Covid misinformation case heads to Supreme Court

WSS

Think you might have Covid

Cognito secures funding to test medical device for Alzheimer's

Think you might have Covid

Vertigo drug brings hope for rare neuron disorder, Niemann

Independent physicians launch a new lobbying group

AI generated plenty of interest at JPM but not a lot of trust

Wikipedia

leisure time

focus

Peter Hotez and the public health issue of online harassment

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

New air purifier tech could be key to improving indoor air quality

Francis Collins on trust in science and how Covid communications failed

Malaria cases in Florida and Texas: Here’s what you need to know

eGenesis tests gene

Guidelines to prevent youth baseball injuries need more muscle

FDA drug safety: Singulair case shows systemic surveillance flaws

Drug repurposing or repositioning? The language matters

The lessons of Aduhelm, an Alzheimer's drug that was not to be

hotspot

Congressmen charge Covid hearing ‘could have been an email’

Woodcock on FDA’s accelerated approval and her next chapter

Do digital therapeutics have a future in medicine?

Quicker fix for pulse oximeters urged during FDA public meeting

Parkinson’s finding may lead to tests and, someday, treatments

Juul spent big to court Black leaders to promote its e

hotspot

entertainment

focus

focus